OPKO Health Inc OPK

Healthcare Medical Care

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

NDAQ:OPK - Post by User

OPKO Health Inc

<< Previous

Bullboard Posts

Next >>

(241)
•••

Post by coolfooldumbguyon Mar 07, 2025 2:27pm

26 Views

Post# 36484154

Still holding this stock.Wow

It is in my portfolio for about a year and it has been a good one for me so far.Well,as of the today's market action,it is giving my portfolio big paper profits of more than $100,000 U.S.

<< Previous

Bullboard Posts

Next >>

Reviving Europe’s tungsten heart